BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Laughon MM, Benjamin DK, Capparelli EV, Kearns GL, Berezny K, Paul IM, Wade K, Barrett J, Smith PB, Cohen-Wolkowiez M. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol. 2011;4:643-652. [PMID: 21980319 DOI: 10.1586/ecp.11.43] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Gastine S, Rashed AN, Hsia Y, Jackson C, Barker CIS, Mathur S, Tomlin S, Lutsar I, Bielicki J, Standing JF, Sharland M. GAPPS (Grading and Assessment of Pharmacokinetic-Pharmacodynamic Studies) a critical appraisal system for antimicrobial PKPD studies - development and application in pediatric antibiotic studies. Expert Rev Clin Pharmacol 2019;12:1091-8. [PMID: 31747323 DOI: 10.1080/17512433.2019.1695600] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
2 Zimmerman KO, Wu H, Laughon M, Greenberg RG, Walczak R, Schulman SR, Smith PB, Hornik CP, Cohen-Wolkowiez M, Watt KM. Dexmedetomidine Pharmacokinetics and a New Dosing Paradigm in Infants Supported With Cardiopulmonary Bypass. Anesth Analg 2019;129:1519-28. [PMID: 31743171 DOI: 10.1213/ANE.0000000000003700] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
3 von Niederhäusern B, Saccilotto R, Schädelin S, Ziesenitz V, Benkert P, Decker ML, Hammann A, Bielicki J, Pfister M, Pauli-Magnus C. Validity of mobile electronic data capture in clinical studies: a pilot study in a pediatric population. BMC Med Res Methodol 2017;17:163. [PMID: 29216831 DOI: 10.1186/s12874-017-0438-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Van Driest SL, Marshall MD, Hachey B, Beck C, Crum K, Owen J, Smith AH, Kannankeril PJ, Woodworth A, Caprioli RM, Choi L. Pragmatic pharmacology: population pharmacokinetic analysis of fentanyl using remnant samples from children after cardiac surgery. Br J Clin Pharmacol 2016;81:1165-74. [PMID: 26861166 DOI: 10.1111/bcp.12903] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
5 Sathe AG, Brundage RC, Ivaturi V, Cloyd JC, Chamberlain JM, Elm JJ, Silbergleit R, Kapur J, Coles LD. A pharmacokinetic simulation study to assess the performance of a sparse blood sampling approach to quantify early drug exposure. Clin Transl Sci 2021;14:1444-51. [PMID: 33742783 DOI: 10.1111/cts.13004] [Reference Citation Analysis]
6 Hornik CP, Wu H, Edginton AN, Watt K, Cohen-Wolkowiez M, Gonzalez D. Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data. Clin Pharmacokinet 2017;56:1343-53. [PMID: 28290120 DOI: 10.1007/s40262-017-0525-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
7 Kipper K, Barker CIS, Standing JF, Sharland M, Johnston A. Development of a Novel Multipenicillin Assay and Assessment of the Impact of Analyte Degradation: Lessons for Scavenged Sampling in Antimicrobial Pharmacokinetic Study Design. Antimicrob Agents Chemother 2018;62:e01540-17. [PMID: 29084754 DOI: 10.1128/AAC.01540-17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
8 Dubrocq G, Rakhmanina N, Phelps BR. Challenges and Opportunities in the Development of HIV Medications in Pediatric Patients. Paediatr Drugs 2017;19:91-8. [PMID: 28074348 DOI: 10.1007/s40272-016-0210-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
9 Allegaert K. Clinical pharmacological studies in children: From exploratory towards confirmation driven methodology. World J Clin Pediatr. 2012;1:3-7. [PMID: 25254160 DOI: 10.5409/wjcp.v1.i2.3] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Frymoyer A, Bonifacio SL, Drover DR, Su F, Wustoff CJ, Van Meurs KP. Decreased Morphine Clearance in Neonates With Hypoxic Ischemic Encephalopathy Receiving Hypothermia. J Clin Pharmacol 2017;57:64-76. [PMID: 27225747 DOI: 10.1002/jcph.775] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
11 Pandya HC, Mulla H, Hubbard M, Cordell RL, Monks PS, Yakkundi S, McElnay JC, Nunn AJ, Turner MA; ESNEE consortium. Essential medicines containing ethanol elevate blood acetaldehyde concentrations in neonates. Eur J Pediatr 2016;175:841-7. [PMID: 26997167 DOI: 10.1007/s00431-016-2714-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
12 Laughon MM, Avant D, Tripathi N, Hornik CP, Cohen-Wolkowiez M, Clark RH, Smith PB, Rodriguez W. Drug labeling and exposure in neonates. JAMA Pediatr 2014;168:130-6. [PMID: 24322269 DOI: 10.1001/jamapediatrics.2013.4208] [Cited by in Crossref: 71] [Cited by in F6Publishing: 52] [Article Influence: 10.1] [Reference Citation Analysis]
13 Gonzalez D, Melloni C, Yogev R, Poindexter BB, Mendley SR, Delmore P, Sullivan JE, Autmizguine J, Lewandowski A, Harper B, Watt KM, Lewis KC, Capparelli EV, Benjamin DK Jr, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee. Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents. Clin Pharmacol Ther 2014;96:429-37. [PMID: 24949994 DOI: 10.1038/clpt.2014.134] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 6.6] [Reference Citation Analysis]
14 Turner MA, Catapano M, Hirschfeld S, Giaquinto C; Global Research in Paediatrics. Paediatric drug development: the impact of evolving regulations. Adv Drug Deliv Rev 2014;73:2-13. [PMID: 24556465 DOI: 10.1016/j.addr.2014.02.003] [Cited by in Crossref: 89] [Cited by in F6Publishing: 69] [Article Influence: 12.7] [Reference Citation Analysis]
15 Clyburne-Sherin AV, Thurairajah P, Kapadia MZ, Sampson M, Chan WW, Offringa M. Recommendations and evidence for reporting items in pediatric clinical trial protocols and reports: two systematic reviews. Trials 2015;16:417. [PMID: 26385379 DOI: 10.1186/s13063-015-0954-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
16 Le J, Bradley JS. Optimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs. J Clin Pharmacol 2018;58 Suppl 10:S108-22. [PMID: 30248202 DOI: 10.1002/jcph.1128] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
17 Himebauch AS, Zuppa A. Methods for pharmacokinetic analysis in young children. Expert Opinion on Drug Metabolism & Toxicology 2014;10:497-509. [DOI: 10.1517/17425255.2014.885502] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
18 Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. Br J Clin Pharmacol. 2015;79:357-369. [PMID: 24325152 DOI: 10.1111/bcp.12305] [Cited by in Crossref: 125] [Cited by in F6Publishing: 87] [Article Influence: 20.8] [Reference Citation Analysis]
19 Samardzic J, Turner MA, Bax R, Allegaert K. Neonatal medicines research: challenges and opportunities. Expert Opin Drug Metab Toxicol 2015;11:1041-52. [PMID: 25958820 DOI: 10.1517/17425255.2015.1046433] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
20 Hahn D, Emoto C, Euteneuer JC, Mizuno T, Vinks AA, Fukuda T. Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Lessons From PBPK Modeling and Clinical Study. Clin Pharmacol Ther 2019;105:761-8. [PMID: 30300922 DOI: 10.1002/cpt.1249] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
21 Chung JK, Hallberg B, Hansen-Pupp I, Graham MA, Fetterly G, Sharma J, Tocoian A, Kreher NC, Barton N, Hellström A, Ley D. Development and verification of a pharmacokinetic model to optimize physiologic replacement of rhIGF-1/rhIGFBP-3 in preterm infants. Pediatr Res 2017;81:504-10. [PMID: 27870826 DOI: 10.1038/pr.2016.255] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
22 Turner MA, Attar S, de Wildt SN, Vassal G, Mangiarini L, Giaquinto C. Roles of Clinical Research Networks in Pediatric Drug Development. Clin Ther 2017;39:1939-48. [PMID: 28943118 DOI: 10.1016/j.clinthera.2017.09.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
23 Gonzalez D, Boggess KA, Cohen-Wolkowiez M. Lessons learned in pediatric clinical research to evaluate safe and effective use of drugs in pregnancy. Obstet Gynecol 2015;125:953-8. [PMID: 25751205 DOI: 10.1097/AOG.0000000000000743] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
24 Barker CIS, Standing JF, Kelly LE, Hanly Faught L, Needham AC, Rieder MJ, de Wildt SN, Offringa M. Pharmacokinetic studies in children: recommendations for practice and research. Arch Dis Child 2018;103:695-702. [PMID: 29674514 DOI: 10.1136/archdischild-2017-314506] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
25 Nikanjam M, Stewart CF, Takimoto CH, Synold TW, Beaty O, Fouladi M, Capparelli EV. Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. Cancer Chemother Pharmacol 2015;75:495-503. [PMID: 25557868 DOI: 10.1007/s00280-014-2667-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
26 Hornik CP, Benjamin DK Jr, Smith PB, Pencina MJ, Tremoulet AH, Capparelli EV, Ericson JE, Clark RH, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act—Pediatric Trials Network. Electronic Health Records and Pharmacokinetic Modeling to Assess the Relationship between Ampicillin Exposure and Seizure Risk in Neonates. J Pediatr 2016;178:125-129.e1. [PMID: 27522443 DOI: 10.1016/j.jpeds.2016.07.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
27 Korth-Bradley JM. The Path to Perfect Pediatric Posology - Drug Development in Pediatrics. J Clin Pharmacol 2018;58 Suppl 10:S48-57. [PMID: 30248197 DOI: 10.1002/jcph.1081] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
28 Maharaj AR, Wu H, Zimmerman KO, Autmizguine J, Kalra R, Al-Uzri A, Sherwin CMT, Goldstein SL, Watt K, Erinjeri J, Payne EH, Cohen-Wolkowiez M, Hornik CP. Population pharmacokinetics of olanzapine in children. Br J Clin Pharmacol 2021;87:542-54. [PMID: 32497307 DOI: 10.1111/bcp.14414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Rashed AN, Jackson C, Gastine S, Hsia Y, Bielicki J, Standing JF, Tomlin S, Sharland M. Pediatric pharmacokinetics of the antibiotics in the access and watch groups of the 2019 WHO model list of essential medicines for children: a systematic review. Expert Rev Clin Pharmacol 2019;12:1099-106. [PMID: 31760892 DOI: 10.1080/17512433.2019.1693257] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
30 Hornik CP, Onufrak NJ, Smith PB, Cohen-Wolkowiez M, Laughon MM, Clark RH, Gonzalez D. Association between oral sildenafil dosing, predicted exposure, and systemic hypotension in hospitalised infants. Cardiol Young 2018;28:85-92. [PMID: 28784200 DOI: 10.1017/S1047951117001639] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
31 England A, Wade K, Smith PB, Berezny K, Laughon M; Best Pharmaceuticals for Children Act — Pediatric Trials Network Administrative Core Committee. Optimizing operational efficiencies in early phase trials: The Pediatric Trials Network experience. Contemp Clin Trials 2016;47:376-82. [PMID: 26968616 DOI: 10.1016/j.cct.2016.03.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
32 Ku LC, Smith PB. Dosing in neonates: special considerations in physiology and trial design. Pediatr Res 2015;77:2-9. [PMID: 25268145 DOI: 10.1038/pr.2014.143] [Cited by in Crossref: 53] [Cited by in F6Publishing: 40] [Article Influence: 7.6] [Reference Citation Analysis]
33 Laughon MM, Chantala K, Aliaga S, Herring AH, Hornik CP, Hughes R, Clark RH, Smith PB. Diuretic exposure in premature infants from 1997 to 2011. Am J Perinatol 2015;32:49-56. [PMID: 24801161 DOI: 10.1055/s-0034-1373845] [Cited by in Crossref: 5] [Cited by in F6Publishing: 18] [Article Influence: 0.7] [Reference Citation Analysis]
34 Rose K, Walson PD. Do the European Medicines Agency Decisions Hurt Pediatric Melanoma Patients? Clin Ther 2017;39:253-65. [PMID: 28159363 DOI: 10.1016/j.clinthera.2017.01.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
35 Tang Girdwood SC, Tang PH, Murphy ME, Chamberlain AR, Benken LA, Jones RL, Stoneman EM, Kaplan JM, Vinks AA. Demonstrating Feasibility of an Opportunistic Sampling Approach for Pharmacokinetic Studies of β-Lactam Antibiotics in Critically Ill Children. J Clin Pharmacol 2021;61:565-73. [PMID: 33111331 DOI: 10.1002/jcph.1773] [Reference Citation Analysis]
36 Gonzalez D, Melloni C, Poindexter BB, Yogev R, Atz AM, Sullivan JE, Mendley SR, Delmore P, Delinsky A, Zimmerman K, Lewandowski A, Harper B, Lewis KC, Benjamin DK Jr, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act--Pediatric Trials Network Administrative Core Committee. Simultaneous determination of trimethoprim and sulfamethoxazole in dried plasma and urine spots. Bioanalysis 2015;7:1137-49. [PMID: 26039810 DOI: 10.4155/bio.15.38] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
37 Rivera-Chaparro ND, Cohen-Wolkowiez M, Greenberg RG. Dosing antibiotics in neonates: review of the pharmacokinetic data. Future Microbiol 2017;12:1001-16. [PMID: 28758800 DOI: 10.2217/fmb-2017-0058] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
38 Beam KS, Aliaga S, Ahlfeld SK, Cohen-Wolkowiez M, Smith PB, Laughon MM. A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants. J Perinatol 2014;34:705-10. [PMID: 25010224 DOI: 10.1038/jp.2014.126] [Cited by in Crossref: 61] [Cited by in F6Publishing: 46] [Article Influence: 8.7] [Reference Citation Analysis]
39 Allegaert K, Langhendries JP, van den Anker JN. Educational paper: Do we need neonatal clinical pharmacologists. Eur J Pediatr. 2012;Epub ahead of print. [PMID: 22588521 DOI: 10.1007/s00431-012-1734-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
40 Kreeftmeijer-Vegter AR, Dorlo TP, Gruppen MP, de Boer A, de Vries PJ. Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome. Br J Clin Pharmacol 2015;80:242-52. [PMID: 25677380 DOI: 10.1111/bcp.12607] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
41 Hahn D, Fukuda T, Euteneuer JC, Mizuno T, Vinks AA, Sadhasivam S, Emoto C. Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and Pediatric Patients. J Clin Pharmacol 2020;60:992-8. [PMID: 32090339 DOI: 10.1002/jcph.1592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Rose K, Walson PD. Do Paediatric Investigation Plans (PIPs) Advance Paediatric Healthcare? Paediatr Drugs 2017;19:515-22. [PMID: 28889403 DOI: 10.1007/s40272-017-0260-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
43 van Hasselt JGC, van Eijkelenburg NKA, Beijnen JH, Schellens JH, Huitema ADR. Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation: Vincristine Clinical Trial Simulation. Pediatr Blood Cancer 2014;61:2223-9. [DOI: 10.1002/pbc.25198] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
44 Cross HR, Harris A, Arias RM, Chambers HF, Fowler VG Jr; Leadership and Operations Center., of the Antibacterial Resistance Leadership Group (ARLG). Transforming Concepts Into Clinical Trials and Creating a Multisite Network: The Leadership and Operations Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64:S8-S12. [PMID: 28350897 DOI: 10.1093/cid/ciw825] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
45 Turner MA. Clinical trials of medicines in neonates: the influence of ethical and practical issues on design and conduct. Br J Clin Pharmacol 2015;79:370-8. [PMID: 25041601 DOI: 10.1111/bcp.12467] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
46 Himebauch AS, Kilbaugh TJ, Zuppa AF. Pharmacotherapy during pediatric extracorporeal membrane oxygenation: a review. Expert Opin Drug Metab Toxicol 2016;12:1133-42. [PMID: 27322360 DOI: 10.1080/17425255.2016.1201066] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
47 Jackson W, Taylor G, Selewski D, Smith PB, Tolleson-Rinehart S, Laughon MM. Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review. Matern Health Neonatol Perinatol 2018;4:23. [PMID: 30473868 DOI: 10.1186/s40748-018-0092-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
48 Thompson EJ, Wu H, Maharaj A, Edginton AN, Balevic SJ, Cobbaert M, Cunningham AP, Hornik CP, Cohen-Wolkowiez M. Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children. Clin Pharmacokinet 2019;58:887-98. [PMID: 30840200 DOI: 10.1007/s40262-018-00733-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
49 Bjergum MW, Barreto EF, Scheetz MH, Rule AD, Jannetto PJ. Stability and Validation of a High-Throughput LC-MS/MS Method for the Quantification of Cefepime, Meropenem, and Piperacillin and Tazobactam in Serum. J Appl Lab Med 2021:jfab036. [PMID: 34086904 DOI: 10.1093/jalm/jfab036] [Reference Citation Analysis]
50 Tanemura N, Sasaki T, Sato J, Urushihara H. Study factors associated with the incompletion of clinical trials that include pediatric patients: a retrospective analysis of the European Clinical Trials Database and a lesson from the European region. Trials 2021;22:204. [PMID: 33706800 DOI: 10.1186/s13063-021-05143-6] [Reference Citation Analysis]
51 Chin WW, Joos A. Moving toward a paradigm shift in the regulatory requirements for pediatric medicines. Eur J Pediatr 2016;175:1881-91. [PMID: 27646479 DOI: 10.1007/s00431-016-2781-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
52 Uribe-Restrepo A, Cossio A, Desai MM, Dávalos D, Castro MDM. Interventions to treat cutaneous leishmaniasis in children: A systematic review. PLoS Negl Trop Dis 2018;12:e0006986. [PMID: 30550538 DOI: 10.1371/journal.pntd.0006986] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
53 Valkenburg AJ, de Leeuw TG, van Dijk M, Tibboel D. Pain in Intellectually Disabled Children: Towards Evidence-Based Pharmacotherapy? Paediatr Drugs 2015;17:339-48. [PMID: 26076801 DOI: 10.1007/s40272-015-0138-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
54 Zimmerman K, Gonzalez D, Swamy GK, Cohen-Wolkowiez M. Pharmacologic studies in vulnerable populations: Using the pediatric experience. Semin Perinatol 2015;39:532-6. [PMID: 26358805 DOI: 10.1053/j.semperi.2015.08.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
55 Manitpisitkul P, Shalayda K, Todd M, Wang SS, Ness S, Ford L. Pharmacokinetics and safety of adjunctive topiramate in infants (1-24 months) with refractory partial-onset seizures: A randomized, multicenter, open-label phase 1 study: Topiramate Pharmacokinetics in Infants. Epilepsia 2013;54:156-64. [DOI: 10.1111/epi.12019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
56 Maharaj AR, Wu H, Hornik CP, Arrieta A, James L, Bhatt-Mehta V, Bradley J, Muller WJ, Al-Uzri A, Downes KJ, Cohen-Wolkowiez M. Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy. J Pharmacokinet Pharmacodyn 2020;47:199-218. [PMID: 32323049 DOI: 10.1007/s10928-020-09684-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Balevic SJ, Cohen-Wolkowiez M. Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children. J Clin Pharmacol 2018;58 Suppl 10:S58-72. [PMID: 30248192 DOI: 10.1002/jcph.1053] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
58 Gostelow M, Gonzalez D, Smith PB, Cohen-Wolkowiez M. Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults. Expert Rev Clin Pharmacol 2014;7:327-40. [PMID: 24716805 DOI: 10.1586/17512433.2014.909281] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
59 Allegaert K. Tailored tools to improve pharmacotherapy in infants. Expert Opin Drug Metab Toxicol 2014;10:1069-78. [PMID: 24961300 DOI: 10.1517/17425255.2014.931937] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
60 Fermini B, Coyne ST, Coyne KP. Clinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development. SLAS Discov 2018;23:765-76. [PMID: 29862873 DOI: 10.1177/2472555218775028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
61 Hornik CP, Atz AM, Bendel C, Chan F, Downes K, Grundmeier R, Fogel B, Gipson D, Laughon M, Miller M, Smith M, Livingston C, Kluchar C, Heath A, Jarrett C, McKerlie B, Patel H, Hunter C; Best Pharmaceuticals for Children Act–Pediatric Trials Network. Creation of a Multicenter Pediatric Inpatient Data Repository Derived from Electronic Health Records. Appl Clin Inform 2019;10:307-15. [PMID: 31067576 DOI: 10.1055/s-0039-1688477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Balevic SJ, Becker ML, Cohen-Wolkowiez M, Schanberg LE. Clinical Trial Design in Juvenile Idiopathic Arthritis. Paediatr Drugs 2017;19:379-89. [PMID: 28612093 DOI: 10.1007/s40272-017-0244-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
63 Hill KD, Sampson MR, Li JS, Tunks RD, Schulman SR, Cohen-Wolkowiez M. Pharmacokinetics of intravenous sildenafil in children with palliated single ventricle heart defects: effect of elevated hepatic pressures. Cardiol Young 2016;26:354-62. [PMID: 26197839 DOI: 10.1017/S1047951115000359] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
64 Samant TS, Mangal N, Lukacova V, Schmidt S. Quantitative clinical pharmacology for size and age scaling in pediatric drug development: A systematic review: A Systematic Review of Pediatric Dosing Approaches. J Clin Pharmacol 2015;55:1207-17. [DOI: 10.1002/jcph.555] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
65 D'Cunha R, Widness JA, Yan X, Schmidt RL, Veng-Pedersen P, An G. A Mechanism-Based Population Pharmacokinetics Model of Erythropoietin in Premature Infants and Healthy Adults Following Multiple Intravenous Doses. J Clin Pharmacol 2019;59:835-46. [PMID: 30618050 DOI: 10.1002/jcph.1368] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
66 Wang J, Edginton AN, Avant D, Burckart GJ. Predicting neonatal pharmacokinetics from prior data using population pharmacokinetic modeling. J Clin Pharmacol 2015;55:1175-83. [PMID: 25907280 DOI: 10.1002/jcph.524] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
67 Girdwood ST, Kaplan J, Vinks AA. Methodologic Progress Note: Opportunistic Sampling for Pharmacology Studies in Hospitalized Children. J Hosp Med 2021;16:35-7. [PMID: 32118552 DOI: 10.12788/jhm.3380] [Cited by in F6Publishing: 3] [Reference Citation Analysis]